IL17A and breast carcinoma: Cochaud et al. also proved, that recombinant IL-17A induces the MAPK pathway by upregulating phosphorylated ERK1/2 in human breast cancer cell lines, thereby promoting proliferation and resistance to conventional chemotherapeutic agents such as docetaxel and stimulates migration and invasion of breast cancer cells [9].